AASLD-EASL HBV Endpoints 2022

Published on 05/08/2022

3-4 June, 2022
Washington, US

ENYO Pharma was attending AASLD-EASL HBV Endpoints 2022 to share news on therapeutic endpoints, trial designs and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D. It was a great opportunity to meet academic, regulatory, pharmaceutical communities and patients in liver disease area.